Empowering Health: The Evolution of Female Diagnosis and Treatment

Global female infertility diagnosis and treatment market is anticipated to grow at a CAGR of 5.6% during the forecast period (2024-2031). The rising trends of surrogacy, the growing infertility rate among females, and new technologies to avoid multiple embryo implants are estimated to be the major factors that are contributing to the market growth. Advancement in IVF treatments has opened up new potential opportunities with positive results of IVF procedures. It is expected to propel the demand for female infertility diagnosis and treatment market during the forecasted period.

Browse the full report description of “Female Infertility Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Diagnosis (Ovulation Testing, Hysterosalpingography (HSG), Hysteroscopy, Imaging Testing, Ovarian Reserve Testing, Hormonal Level Testing, Genetic Testing, and Others), by Treatment (Drugs, Surgery, Intrauterine Insemination (IUI), and Assisted Reproductive Technology (ART)), and by End-User (Hospitals and Clinics, Homecare, and Pathology and Diagnostic Centers) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/female-infertility-market-size

Recent Developments in the Female Infertility Diagnosis and Treatment Market

• In February 2024, Catalent, Inc. and Novo Holdings, announced that they have entered into a merger agreement. Novo Holdings has acquired Catalent in an all-cash transaction, valuing Catalent at $16.5 billion. The acquisition is aimed at Novo Holdings’ mandate to invest in high-quality life sciences companies. 

• In September 2023, Femasys Inc., a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead late-clinical stage.

Market Coverage

• The market number available for – 2023-2031

• Base year- 2023

• Forecast period- 2024-2031

• Segment Covered-

o By Diagnosis

o By Treatment

o By End User

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- AbbVie Inc., Bayer AG, CooperSurgical Inc., Eli Lilly and Co., and Merck KGaA, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Female Infertility Diagnosis and Treatment Market Report Segment

By Diagnosis

• Ovulation Testing
• Hysterosalpingography (HSG)
• Hysteroscopy
• Imaging Testing
• Ovarian Reserve Testing
• Hormonal Level Testing
• Genetic Testing
• Others

By Treatment

• Drugs 
• Surgery
• Intrauterine Insemination (IUI)
• Assisted Reproductive Technology (ART)

By End User

• Hospitals and Clinics
• Homecare
• Pathology
• Diagnostic Centers

Global Female Infertility Diagnosis and Treatment Market Report Segment by Region

North America

• United States

• Canada 

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/female-infertility-market-size